Press Releases - Ipsen Corporate

February 13, 2020

Ipsen presents its 2019 results, provides 2020 guidance and updates 2022 financial outlook

Financial results

Ipsen – Full Year 2019 – English – Finale clear2.pdf

Ipsen FY2019 presentation.pdf

January 24, 2020

Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria

Press Releases

PalovaroteneP3pause-PressRelease012420_EN.pdf

January 14, 2020

Ipsen appoints Steven Hildemann, MD., PhD as Executive Vice President, Chief Medical Officer

Press Releases

Ipsen_CMOannouncement-pressrelease_EN.pdf

January 6, 2020

Dysport® (clostridium botulinum type A toxin-haemagglutinin complex) now approved in the UK for symptomatic treatment of upper limb spasticity in children with cerebral palsy

Press Releases

Press Release – Dysport PUL licence update_Final_English.pdf

December 18, 2019

Ipsen Announces Departure of David Meek as Chief Executive Officer

Press Releases

David_Meek-News_Release_171219_EN.pdf

December 6, 2019

Ipsen Initiates Partial Clinical Hold for Palovarotene IND120181 and IND135403 Studies

Press Releases

Palovarotene_FDA_Partial_Clinical_Hold-News_Release_061219.pdf

November 5, 2019

Ipsen appoints Howard Mayer, M.D. as Executive Vice President and Head of Research and Development

Press Releases

HeadR&D-News-Release-EN.pdf

November 5, 2019

Proposed reclassification of Ipsen shares held by Mayroy

Press Releases

NewsRelease-Mayroy-EN.pdf

October 31, 2019

Ipsen presents new analyses utilizing modern data mining approaches at ISPOR Europe 2019

Press Releases

Ipsen ISPOR Europe curtain raiser_EN.pdf

October 24, 2019

Ipsen delivers strong double-digit sales growth for the third quarter of 2019 and confirms full year 2019 guidance

Financial results

Q3 2019 EN – Final.pdf

Q3 2019 Presentation vfinale.pdf

October 16, 2019

Ipsen and Blueprint Medicines announce exclusive global license agreement to develop and commercialize BLU-782 for the treatment of fibrodysplasia ossificans progressiva (FOP)

Press Releases

Download.pdf

September 26, 2019

Ipsen showcases studies at the ESMO 2019 Congress highlighting progress in new approaches for difficult-to-treat cancers

Press Releases

.pdf

September 23, 2019

Ipsen announces positive results from Phase IIIb/IV ENGAGE study of the combination of Dysport® (abobotulinumtoxinA) with Guided Self-rehabilitation Contracts in adult patients with upper and lower limb spastic hemiparesis

Press Releases

September 20, 2019

Ipsen to present new data at 13th Annual Conference of the International Liver Cancer Association (ILCA 2019)

Press Releases

Ipsen ILCA MAIC Press Release_EN.pdf

September 8, 2019

Ipsen and Servier announce initial Phase II/III clinical data evaluating investigational liposomal irinotecan (ONIVYDE®) as a second-line treatment for small cell lung cancer (SCLC) at the IASLC 2019 World Conference on Lung Cancer

Press Releases

SEPT19_Ipsen Onivyde SCLC World Lung Press Release FINAL_EN.pdf

July 25, 2019

Ipsen delivers strong results for the first half of 2019 with robust double-digit sales growth and improved Core Operating margin and upgrades its guidance for full year 2019

Financial results

Download.pdf

H1 2019 presentation FINAL.pdf

July 5, 2019

Ipsen and Servier announce initial Phase 1/2 clinical data evaluating liposomal irinotecan (ONIVYDE®) as an investigational first-line treatment for metastatic pancreatic cancer at ESMO 21st World Congress on Gastrointestinal Cancer

Press Releases

190705_Ipsen Onivyde 1st Line World GI Data Presentation Press Release ENGLISH FINAL.pdf

June 25, 2019

Disclosure of transactions in own shares between 18/06/2019 and 21/06/2019

Press Releases

Download.pdf

June 18, 2019

Ipsen initiates a share buyback program to cover its new free share allocation plan

Press Releases

Download.pdf

June 12, 2019

Debiopharm and Ipsen extend their strategic Decapeptyl® (triptorelin) partnership for another 15 years

Press Releases

Debiopharm and Ipsen agreement renewal.pdf

May 24, 2019

New investigational clinical data for Ipsen’s oncology products in 11 solid tumor types to be presented at 2019 ASCO Annual Meeting

Press Releases

190522-Ipsen-Oncology-ASCO-Curtain-Raiser.pdf

May 14, 2019

Ipsen to host an Investor Day to highlight its innovative R&D pipeline and provide financial outlook for 2022

Conferences & Roadshows

Download.pdf

Ipsen -Investor-Day-2019.pdf

April 24, 2019

Ipsen reports strong double-digit sales growth in First Quarter 2019 and confirms Full Year 2019 financial targets

Financial results

.pdf

April 18, 2019

Ipsen Completes Acquisition of Clementia Pharmaceuticals

Press Releases

Download.pdf

April 12, 2019

Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A.

Press Releases

April 9, 2019

Clementia Pharmaceuticals Inc. Shareholders Approve Plan of Arrangement With Ipsen S.A.

Press Releases

March 27, 2019

Ipsen publishes its 2018 Registration Document

Annual report

Download.pdf

March 6, 2019

Ipsen to Present Improvements to Somatuline® Autogel® Pre-filled Syringe at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference

Press Releases

ENG-Ipsen_ENETS_Abstract_FINAL.pdf

February 28, 2019

Ipsen to Present New Data on Enhancement of Patient Care at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference

Press Releases

ENG-Ipsen_ENETS_CR_FINAL.pdf

February 25, 2019

Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio

Press Releases

Ipsen-to-acquire-Clementia-Final.pdf

Ipsen-to-acquire-Clementia1.pdf

February 14, 2019

Ipsen delivers strong 2018 results and expects continued sales and profit growth in 2019

Financial results

Ipsen-Full-Year-2018-Financial-Results-FINAL.pdf

FY-2018-Presentation-FINAL-vf.pdf

January 18, 2019

Patients living with spasticity want long-lasting symptom relief

Press Releases

Carenity-Infographic_180119.pdf

January 17, 2019

Ipsen presents the results of the first in-human study of a recombinant fast-acting neurotoxin (rBoNT-E) at TOXINS 2019

Press Releases

eng-_ipsen_toxins_pr-bont-e_170119_final.pdf

January 11, 2019

Ipsen demonstrates leadership position in neurotoxin research with strong presence at TOXINS 2019

Press Releases

eng-ipsen_toxins_cr_final.pdf

December 5, 2018

Exelixis and Ipsen initiate phase 3 pivotal trial (COSMIC-312) of cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced hepatocellular carcinoma

Press Releases

ipsen-v-eng-18-12-05_final_exel-and-ipsen-press-release_1l-hcc-cosmic-312-trial-initiation-exel-version.pdf

November 20, 2018

Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide (IPN01087)

Press Releases

eng-ipn01087_phasei-ii_first_patients_clean.pdf

November 15, 2018

European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the treatment of hepatocellular carcinoma in adults previously treated with sorafenib

Press Releases

engl-eu_approval_cabometyx_2l_hcc_final1.pdf

October 25, 2018

Ipsen delivers strong sales growth of 20.2% for the third quarter of 2018 and confirms full year guidance

Financial results

ipsen-q3-2018-sales-vf.pdf

October 12, 2018

Ipsen to present new data from its oncology portfolio at the 2018 European Society for Medical Oncology (ESMO) congress

Press Releases

esmo-curtain-raiser-eng.pdf

September 21, 2018

Ipsen receives positive CHMP opinion for Cabometyx® (cabozantinib) for the second-line treatment of patients with hepatocellular carcinoma (HCC)

Press Releases

September 21, 2018

Ipsen receives positive CHMP opinion for Cabometyx® (cabozantinib) for the second-line treatment of patients with hepatocellular carcinoma (HCC)

Press Releases

chmp-positive-opinion-cabo-hcc_210918_finalv2.pdf

July 26, 2018

Ipsen delivers strong results for the first half of 2018 with sales growth of 21.5% and upgrades its guidance for full year 2018

Financial results

ipsen-half-year-2018-financial-results-final.pdf

h1-2018-presentation-final1.pdf

ipsen-q3-2018-sales-v14.pdf

July 19, 2018

Ipsen and BioLabs to open new Innovation Center in Cambridge (U.S.) to foster development of new therapies for patients

Press Releases

ipsen_biolabs_announcement_19-07-18.pdf

July 4, 2018

Ipsen announces new clinical data to be presented at ISPRM 2018 demonstrating commitment to neurotoxin research

Press Releases

isprm_curtain-raiser_030718us.pdf

July 4, 2018

Ipsen announces CELESTIAL phase 3 pivotal trial results in the New England Journal of Medicine

Press Releases

celestial-phase-3-trial-results-in-nejm_040718.pdf

June 4, 2018

Ipsen initiates a share buyback program to cover its free share allocation and employee share plans

Press Releases

May 30, 2018

Combined Shareholders’ Meeting of 30 May 2018

Press Releases

1-preliminary-notice-to-the-meeting-published-in-the-french-balo-french-only-agm-30-may-2018.pdf

2-preliminary-notice-to-the-meeting-translation-for-information-agm-30-may-2018.pdf

3-information-voting-rights-shares-agm-30-may-2018.pdf

4-shareholders-meeting-notice-published-in-the-french-balo-french-only-agm-30-may-2018.pdf

5-meeting-notice-agm-30-may-2018.pdf

6-voting-or-proxy-form-agm-30-may-2018.pdf

7-availability-and-consultation-of-preparatory-documentation-for-the-agm-agm-30-may-2018.pdf

8-registration-document-2017-agm-30-may-2018.pdf

9-report-of-the-board-of-directors-agm-30-may-2018.pdf

10-voting-results-agm-30-may-2018.pdf

11-press-release-post-agm-agm-30-may-2018.pdf

May 30, 2018

Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at the Combined Shareholders’ Meeting on 30 May 2018

Press Releases

projet-de-descriptif-du-programme-de-rachat-soumis-a-lag-english-v6.pdf

projet-de-descriptif-du-programme-de-rachat-soumis-a-lag-english-vf2.pdf

May 29, 2018

Ipsen announces clinical data to be presented at ASCO demonstrating its commitment to patients with cancer

Press Releases

2018-05-29-asco-curtain-raiser-en.pdf

May 29, 2018

Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development Partnership

Press Releases

2018-05-29-ipsen-md-anderson-joint-press-release-en.pdf

May 17, 2018

European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma

Press Releases

2018-05-17-eu-approval-cabometyx-rcc-1l-final-final.pdf

April 26, 2018

Ipsen reports strong first quarter 2018 sales growth of 23.1% at constant exchange rates

Financial results

ipsen-q1-2018-sales-v14.pdf

ipsen-q1-2018-sales-vf.pdf

ipsen-q1-2018-sales-final.pdf

ipsen-ventes-t1-2018-finale.pdf

ipsen-q1-sales-results.pdf

March 28, 2018

Ipsen announces EMA validation of filing of a new application for additional indication for Cabometyx®, for patients with previously treated advanced Hepatocellular Carcinoma (HCC).

Press Releases

pr-acceptance-filing-cabometyx-2l-hcc-v2.pdf

March 26, 2018

Ipsen publishes its 2017 Registration Document

Annual report

ipsen_ddr_2017_complet_clean-vdef.pdf

ipsen_ddr_2017_va_complet_clean-003.pdf

March 23, 2018

Ipsen receives positive CHMP opinion for Cabometyx® (cabozantinib) for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma

Press Releases

2018-03-23-pr-chmp-positive-opinion-cabometyx-eu-1lrcc-final-final.pdf

March 13, 2018

Ipsen appoints Ivana Magovčević-Liebisch Ph.D., J.D. and Régis Mulot to Executive Leadership Team

Press Releases

appointment-of-ivana-magovcevic-liebisch-and-regis-mulot-en-with-photos.pdf

March 6, 2018

Ipsen announces 18 posters to be presented at the 15th Annual ENETS Conference

Press Releases

2018-01-16-enet-en.pdf

February 21, 2018

Arix Bioscience and Ipsen sign a strategic agreement to develop and commercialise innovative therapies

Press Releases

arix-ipsen-angl-vfinal.pdf

February 15, 2018

Ipsen delivers strong 2017 results with 21.1% sales growth and Core operating margin increase of 3.4 points and expects significant further growth in sales and margin in 2018

Financial results

fy-2017-presentation-final.pdf

February 7, 2018

Ipsen announces eight oral presentations from its Neurosciences portfolio at the 10th World Congress for Neurorehabilitation (WCNR)

Press Releases

07-02-2018-wcnr-mumbai-dysport-en.pdf

January 29, 2018

Dr Sotirios G. Stergiopoulos appointed as Ipsen Chief Medical Officer

Press Releases

2018-01-26-dr-sotirios-stergiopoulos-appointed-chief-medical-officer-ipsen_final.pdf

January 16, 2018

Ipsen announces 13 posters and 1 oral presentation at the 2018 ASCO Gastrointestinal Symposium

Press Releases

2018-01-16-asco-gi-curtain-raiser-en-final.pdf

January 16, 2018

Ipsen and Exelixis announce phase 3 trial results of cabozantinib demonstrating significant overall survival benefit in patients with previously treated advanced hepatocellular carcinoma

Press Releases

2018-16-01-asco-gi-celestial-phase-3-results.pdf

January 12, 2018

Ipsen appoints Richard Paulson Executive Vice-President and Chief Executive Officer of Ipsen North America

Press Releases

12-01-2018-appointment-of-richard-paulson-evp-and-ceo-north-america_final.pdf

January 2, 2018

Ipsen announces it is no longer eligible for the PEA-PME scheme

Other

ipsen-annonce-ne-plus-etre-eligible-au-dispositif-pea-pme.pdf

ipsen-announces-it-is-no-longer-eligible-for-the-pea-pme-scheme-2.pdf

December 9, 2017

Ipsen announces its corporate agenda for 2018

Other

2018-financial-agenda.pdf

November 29, 2017

Ipsen announces publication in Neurology of results of two studies demonstrating the efficacy and safety of Dysport® (abobotulinumtoxinA) in adult patients with lower limb spasticity

Press Releases

29-11-2017-dysport-all-neurology-journal-final-en.pdf

October 26, 2017

Ipsen delivers strong sales growth of 22.6% for the third quarter of 2017 and confirms full year guidance

Financial results

ipsen-q3-2017-sales1.pdf

October 16, 2017

Ipsen announces that phase 3 CELESTIAL trial of cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma

Press Releases

16-10-2017-ipsen-celestial-os-en-final-final.pdf

September 19, 2017

Ipsen receives approval from European Commission for Xermelo® (telotristat ethyl) for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analogue therapy

Press Releases

19-09-2017-ipsen-eu-approval-xermelo-carcinoid-syndrome-final.pdf

September 18, 2017

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome

Press Releases

18-09-2017-approval-somatuline-us-carcinoid-syndrom-final.pdf

September 9, 2017

Ipsen and Exelixis announce results from Phase 2 CABOSUN trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma at ESMO 2017

Press Releases

10-09-2017-ipsen-cabosun-esmo-2017-1.pdf

September 8, 2017

Ipsen receives validation from European Medicines Agency for the application of a new indication for Cabometyx® (cabozantinib) for first-line treatment of advanced renal cell carcinoma in adults

Press Releases

pr-acceptance-filing-cabometyx-1st-line-rcc-update-2nd-line-rcc_final-clean.pdf

September 4, 2017

Ipsen announces 16 abstract presentations of oncology portfolio at European Society of Medical Oncology congress

Press Releases

04-09-2017-ipsen-esmo-curtain-raiser-en-final.pdf

August 16, 2017

Exelixis submits U.S. supplemental new drug application for Cabometyx^®(Cabozantinib) for the treatment of previously untreated advanced kidney cancer

Press Releases

17-08-16-exelixis-cabosun-1l-rcc-snda-submission-press-release.pdf

July 27, 2017

Ipsen delivers strong sales growth of 18.8% in the first half of 2017 and upgrades its guidance for full year 2017

Financial results

half-year-2017-financial-report.pdf

h1-2017-financial-results-presentation2.pdf

July 21, 2017

Ipsen receives positive CHMP opinion for approval of Xermelo® (telotristat ethyl), for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analogue therapy

Press Releases

ipsen-receives-positive-chmp-opinion-for-approval-of-xermelo.pdf

July 10, 2017

Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETY or Opdivo and Yervoy® in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma.

Press Releases

pr-exelixis-170710.pdf

July 3, 2017

Somatuline® Autogel® 120 mg receives Japanese approval for a new indication for the treatment of gastro-entero-pancreatic neuroendocrine tumors

Press Releases

03-07-2017-ipsen-teijin-somatuline-gep-net-approval-japan1.pdf

June 30, 2017

Ipsen announces co-promotion agreement with Saol Therapeutics to promote Dysport® (abobotulinumtoxinA) in the United States

Press Releases

30-06-2017-ipsen-sao-co-promotion-final-en.pdf

June 19, 2017

Ipsen and its partner Exelixis announce independent radiology committee review confirms results from Phase 2 CABOSUN trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma

Press Releases

170619-ipsen-cabosun-eng-def.pdf

June 16, 2017

Ipsen announces FDA approval of Dysport® (abobotulinumtoxinA) for the treatment of lower limb spasticity in adults

Press Releases

16-06-2017-snda-dysport-all-us-final.pdf

June 15, 2017

Ipsen’s Partner Exelixis Announces Initiation of Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors.

Press Releases

pr-exelixis-170615.pdf

June 8, 2017

Ipsen initiates share buy-back program to cover its free performance share allocation plan

Press Releases

June 7, 2017

Combined Shareholders’ Meeting of 7 June 2017

Press Releases

1-preliminary-notice-to-the-meeting-published-in-the-french-balo-french-only-agm-7-june-2017.pdf

2-preliminary-notice-to-the-meeting-translation-for-information-agm-7-june-2017.pdf

3-information-voting-rights-shares-agm-7-june-2017.pdf

4-resolutions-agm-7-june-2017.pdf

5-shareholders-meeting-notice-published-in-the-french-balo-french-only-agm-7-june-2017.pdf

6-meeting-notice-agm-7-june-2017.pdf

7-voting-or-proxy-form-agm-7-june-2017.pdf

8-availability-and-consultation-of-preparatory-documentation-for-the-agm-agm-7-june-2017.pdf

9-registration-document-2016-agm-7-june-2017.pdf

10-presentation-agm-7-june-2017.pdf

11-voting-results-agm-7-june-2017.pdf

12-press-release-post-agm-agm-7-june-2017.pdf

June 7, 2017

Combined Shareholders’ Meeting of IPSEN S.A. held on 7 June 2017

Press Releases

Combined-Shareholders-Meeting-of-IPSEN-S.A.-held-on-7-June-2017.pdf

June 1, 2017

Ipsen announces new data to be presented at ASCO in line with its continued commitment to Oncology research

Press Releases

ipsen-asco-curtain-raiser-eng-def.pdf

May 11, 2017

Ipsen presents its new strategy and improved 2020 financial targets

Press Releases

ipsen-presente-sa-nouvelle-strategie-et-des-objectifs-financiers-releves-pour-2020.pdf

ipsen-presents-its-new-strategy-and-improved-2020-financial-targets-2.pdf

May 8, 2017

Ipsen completes acquisition of select Consumer Healthcare products from Sanofi

Press Releases

ipsen-completes-acquisition-of-select-consumer-healthcare-products-from-sanofi-2.pdf

ipsen-finalise-lacquisition-dune-selection-de-produits-de-sante-grand-public-de-sanofi.pdf

April 27, 2017

Ipsen reports strong first quarter 2017 sales growth of 19,1%

Financial results

ipsen-q1-2017-sales.pdf

April 25, 2017

Resolutions submitted to Ipsen’s Shareholders’ Meeting on June 7, 2017

Press Releases

resolutions-to-2017-shareholders-meeting.pdf

April 14, 2017

Ipsen appoints Dr. Alexandre Lebeaut as Executive Vice-President, R&D, and Chief Scientific Officer

Press Releases

14-04-2017-pr-alexandre-lebeaut-evp_rd-and-cso-ipsen-final.pdf

April 3, 2017

Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals

Press Releases

03-04-2017-closing-merrimack-onivyde-final.pdf

March 28, 2017

The Ipsen Group publishes its 2016 Registration Document

Annual report

March 13, 2017

Ipsen announces MHRA approval of new indication for Decapeptyl® for the treatment of pre-menopausal women with early stage breast cancer

Press Releases

pr-mhra-approval-of-new-indication-for-decapeptyl.pdf

March 9, 2017

Ipsen announces data presentations of lanreotide (Somatuline® Autogel®), telotristat ethyl and the investigational compound 177Lu-OPS201 at the European Neuroendocrine Tumor Society (ENETS) 2017 conference

Press Releases

09-03-2017-ipsen-enets-curtain-raiser_final.pdf

March 2, 2017

Ipsen appoints Benoit Hennion as Executive Vice President and President, Primary Care

Press Releases

2017-03-02-pr-benoit-hennion-evp-pdt-primary-care.pdf

March 1, 2017

Ipsen’s Partner Lexicon Pharmaceuticals Announces That FDA Approves Lexicon Drug Xermelo™ (Telotristat ethyl) 250 mg as First and Only Oral Treatment for Carcinoid Syndrome Diarrhea in Cancer Patients with Metastatic Neuroendocrine Tumors.

Press Releases

pr-lexicon-170301.pdf

February 27, 2017

Ipsen’s partner Exelixis announces clinical collaboration with Bristol Myers Squibb for late-stage combination trial in first-line renal cell carcinoma.

Press Releases

pr-exelixis-170227.pdf

February 23, 2017

Ipsen delivers strong 2016 results and expects further sales growth and margin enhancement for 2017

Financial results

full-year-2016-results.pdf

fy-2016-results-transcript.pdf

February 13, 2017

Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi

Press Releases

ipsen-to-acquire-a-portfolio-of-select-consumer-healthcare-products-from-sanofi-2.pdf

January 31, 2017

Ipsen to acquire Primary Care platform in Italy from Akkadeas Pharma

Press Releases

pr-project-serpico-vdef.pdf

January 20, 2017

Ipsen appoints Harout Semerjian as President, Head of Specialty Care International Region & Global Franchises

Press Releases

2017-01-20-pr-harout-semerjian-final-final-en.pdf

January 9, 2017

Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals

Press Releases

09-01-2017-final-ipsen-press-release_merrimack-onivyde.pdf

09-01-2017-cp-merrimack-onivyde-final-fr2.pdf

December 21, 2016

Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include Canada

Press Releases

21-12-2016-joint-pr-exelixis-cabometyx-canada-final.pdf

December 13, 2016

Ipsen announces its corporate agenda for 2017

Press Releases

December 12, 2016

Claude Bertrand to step down as Executive Vice President, R&D, Chief Scientific Officer of Ipsen

Press Releases

2016-12-12-pr-claude-bertrand_alexandre-lebeaut-final.pdf

October 26, 2016

Ipsen reports 12.2% sales growth for the third quarter of 2016 and raises full year guidance

Financial results

pr-q3-2016-sales.pdf

October 20, 2016

The 2016 Georges Mathé Prize recognizes research on the immunological determinants of the response to breast cancer treatment

Press Releases

30205349966_1ac8f6f57f_k.jpg.pdf

October 10, 2016

Ipsen and its partner Exelixis announce positive results from phase 2 CABOSUN trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma presented at the European Society for Medical Oncology (ESMO) 2016 congress

Press Releases

10-10-2016-ipsen-pr-cabosun-data-final-2.pdf

October 7, 2016

Ipsens’ partner, Exelixis, announced phase 1 trial results for cabozantinib in combination with nivolumab in advanced genitourinary tumors

Press Releases

exelixis-announces-phase-1-trial-results-for-cabozantinib-in-combination-with-nivolumab-in-advanced-genitourinary-tumors-07102016.pdf

September 27, 2016

Ipsen announces data presentations of cabozantinib (Cabometyx™), lanreotide (Somatuline® Autogel®) and telotristat ethyl* at the European Society for Medical Oncology (ESMO) 2016 congress

Press Releases

27-09-2016-ipsen-esmo-curtain-raiser-final-pr.pdf

September 14, 2016

European Commission approves Ipsen’s Cabometyx™ (cabozantinib) Tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy

Press Releases

pr-ipsen-eu-approval-cabometyx-2nd-line-rcc-finaldef.pdf

August 1, 2016

Ipsen Announces FDA Approval of Dysport^® (abobotulinumtoxinA) for injection for the treatment of Lower Limb Spasticity in children aged two and older.

Press Releases

pr-approval-dysport-us-pll.pdf

July 28, 2016

Supplemental Application Filed for Somatuline^®in Japan for Additional Indication of Neuroendocrine Tumors

Press Releases

pr_japan_somatuline_final.pdf

July 28, 2016

Ipsen’s First Half 2016 Results

Financial results

pr-half-year-results-2016.pdf

presentation-h12016-final.pdf

July 23, 2016

Ipsen annonce l’autorisation par la FDA de Dysport^® (abobotulinumtoxinA) injection dans le traitement de la spasticité des membres inférieurs chez l’enfant âgé de 2 ans et plus

Press Releases

July 22, 2016

Ipsen and its partner Exelixis receive positive CHMP opinion for Cabometyx™ (cabozantinib) for the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy

Press Releases

22-07-2016-pr-chmp-positive-opinion-cabometyx-eu-ema-final.pdf

July 18, 2016

Ipsen announces the acceptance by the European Medicines Agency of the marketing authorization application for telotristat etiprate to treat carcinoid syndrome caused by neuroendocrine tumors, in combination with somatostatin analogues

Press Releases

pr-acceptance-filing-telotristat-etiprate-final.pdf

July 11, 2016

David Meek appointed as Chief Executive Officer of Ipsen

Press Releases

11-07-2016-pr-david-meek-new-ceo-of-ipsen.pdf

June 8, 2016

Ipsen successfully issues inaugural €300 million 7-year Notes

Press Releases

ipsen-bond-pr-english-vfinal.pdf

June 5, 2016

Exelixis and its partner Ipsen announce positive overall survival results from subgroup analyses of phase 3 trial of CABOMETYX™ (cabozantinib) tablets in advanced renal cell carcinoma at 2016 ASCO annual meeting

Press Releases

ipsen-final-pr-exelixis-and-ipsen-cabometyx-meteor-subgroups1.pdf

June 5, 2016

The Ipsen Group launches an employee shareholding plan

Press Releases

espp-pr-final-vdef.pdf

June 4, 2016

Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO

Press Releases

ipsen-final-pr-exelixis-and-ipsen-cabometyx-meteor-os-data-1.pdf

May 31, 2016

Combined Shareholders’ Meeting of 31 May 2016

Press Releases

2015-registration-document-2.pdf

31-05-2016-press-release-post-shareholders-meeting.pdf

availability-of-preparatory-documentation-for-the-shareholders-meeting1.pdf

avis-de-convocation-in-french-only-2.pdf

avis-prcalable-balo-in-french-only.pdf

information-regarding-the-total-number-of-shares-and-voting-rights-as-at-13-april-2016-2.pdf

ipsen-convocation-2016-english.pdf

ipsen-shareholders-meeting-31-may-2016-results.pdf

voting-or-proxy-form1.pdf

May 31, 2016

Eugenia Litz is appointed as Vice President Investor Relations of Ipsen

Press Releases

pr-appointment-ipsen-eugenia-litz-final.pdf

May 30, 2016

Ipsen’s partner, Lexicon, announced FDA Priority Review of new drug application for telotristat etiprate for the treatment of carcinoid syndrome

Press Releases

pr-lexicon-fda-priority-review-for-telotristat-etiprate2.pdf

May 22, 2016

Ipsen’s partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate that cabozantinib significantly improved progression-free survival versus sunitinib in previously untreated advanced renal cell carcinoma

Press Releases

23-05-2016-pr-final-final-ipsen-cabosun-exelixis-phase-ii-1st-line-rcc.pdf

May 16, 2016

Ipsen partners with IMCB to advance understanding and research of botulinum neurotoxin biology

Press Releases

pr-ipsen-imcb-ipsen-botulinum-toxin-intracellular-trafficking1.pdf

May 2, 2016

Oncodesign and Ipsen enter into a strategic partnership in oncology and Oncodesign joins Ipsen’s Paris-Saclay Campus

Press Releases

03-05-2016-joint-pr-ipsen-oncodesign-rd-campus-les-ulis-final.pdf

April 27, 2016

Ipsen’s first quarter 2016 sales up 4.7%

Financial results

pr-results-q1-2016-final2-28042016.pdf

April 25, 2016

Probi and Ipsen sign extensive Primary Care distribution agreement for probiotic LP299V®, Lactobacillus plantarum 299v

Press Releases

probi-and-ipsen-joint-pr-final.pdf

April 25, 2016

Ipsen is pleased to announce that its partner Exelixis obtained FDA Approval of CABOMETYX™ (cabozantinib) tablets for patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy

Press Releases

25-04-2016-cabozantinib-approval-rcc-us-final.pdf

April 4, 2016

Dassault Systèmes and Ipsen sign collaborative agreement to develop innovative programs to support Ipsen’s drug discovery

Press Releases

05-04-2016-joint-pr-ipsen-dassault-systemes_final.pdf

March 30, 2016

The Ipsen Group publishes its 2015 Registration Document

Annual report

PR-DDR.pdf

March 7, 2016

Ipsen and PeptiMimesis announce a research partnership in oncology

Press Releases

2016-03-08-peptimimesis-ipsen-en-final.pdf

March 1, 2016

Exelixis and Ipsen enter into exclusive licensing agreement to commercialize and develop novel cancer therapy Cabozantinib in regions outside the United States, Canada and Japan

Press Releases

01-03-2016-pr-exelixis-ipsen-cabozantinb-final-2.pdf

March 1, 2016

Ipsen’s 2015 results and 2016 financial objectives

Financial results

01-03-2016-pr-fy15-results-final.pdf

01-03-2016-prez-ir-results-2015-final.pdf

February 16, 2016

Ipsen enters into a licensing agreement with 3B Pharmaceuticals to develop novel radiopharmaceuticals in oncology

Press Releases

17-02-2016-pr-ipsen-3bp_radiopharmaceuticals-final.pdf

February 15, 2016

Changes to Ipsen corporate governance

Press Releases

pr-governance-feb-16-2016-final1.pdf

January 25, 2016

Ipsen announces publication in Pediatrics of the results of the phase III randomized study showing the efficacy and safety of Dysport^® (abobotulinumtoxinA) in children with dynamic equinus foot deformity due to cerebral palsy

Press Releases

pr-dysport-pediatric-lower-limb-spasticitiy-pediatrics-article-in-pediatrics.pdf

January 5, 2016

Ipsen and Galderma expand current distribution agreement for Dysport^® in aesthetic indications to some key Asia-Pacific territories

Press Releases

06-01-2016-pr-ipsen-galderma-apac-dysport-aesthetics.pdf

December 16, 2015

Ipsen announces its corporate agenda for 2016

Press Releases

17-12-2015-pr-ipsen-financial-agenda-2016-final.pdf

November 30, 2015

Ipsen’s partner Lexicon announced that Telotristat Etiprate had achieved positive top-line results in second phase 3 clinical trial

Press Releases

telotristat-etiprate-positive-top-line-results-in-second-phase-3.pdf

November 18, 2015

Ipsen and Interprotein enter into a research collaboration for novel peptides in endocrinology

Press Releases

2015-11-19-pr-ipsen-interprotein-peptides-cushing-endocrinology-final.pdf

October 28, 2015

Ipsen: sales in the 3rd quarter and first nine months of 2015

Press Releases

2015-10-29-pr-q3-9-month-sales-final.pdf

October 27, 2015

Telesta Therapeutics and Ipsen announce exclusive license agreement for MCNA for the treatment of non-muscle invasive bladder cancer in major ex-United States territories

Press Releases

10-28-2015-pr-ipsen-telesta-mcna-bladder-final.pdf

October 25, 2015

Ipsen and EpiVax collaborate to produce next generation botulinum toxins

Press Releases

2015-10-26-ipsen-epivax-next-generation-toxins.pdf

October 21, 2015

Ipsen presents additional results from a Phase III clinical trial of the investigational use of Dysport® in children with spastic equinus foot deformity due to cerebral palsy

Press Releases

2015-10-pr-dysport-final-results-phase-iii-pll-final.pdf

October 18, 2015

Ipsen’s partner Lexicon announced at the 2015 Neuroendocrine Tumor Society Annual Symposium (Austin, Texas) that telotristat etiprate was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study in cancer patients whose carcinoid syndrome was not adequately controlled by somatostatin analog (SSA) therapy.

Press Releases

telotristat-etiprate-phase-3-texas-2015.pdf

September 30, 2015

Ipsen announces release of an additional batch of Increlex® in the U.S.

Press Releases

2015-10-01-pr-increlex-resupply-corporate-final-final.pdf

September 30, 2015

Stéphane Bessette is appointed Executive Vice President, Human Resources of Ipsen

Press Releases

2015-10-01-pr-stephane-bessette-evp-rh-final-final.pdf

September 28, 2015

Ipsen’s partner Lexicon presents phase III TELESTAR study data at ECC 2015 (Vienna, Austria) showing that telotristat etiprate reduces the average number of daily bowel movements in patients with carcinoid syndrome not adequately controlled by somatostatin analogues.

Press Releases

lexicon-telotristat-etiprate.pdf

August 30, 2015

Ipsen announces publication in The Lancet Neurology of the results of the phase III randomized study (NCT01313299) showing efficacy and safety of Dysport® (abobotulinumtoxinA) in adult patients with upper limb spasticity (ULS)

Press Releases

2015-08-31-lancet-neurology-dysport-uls-en-final.pdf

August 2, 2015

Ipsen’s partner, Lexicon Pharmaceuticals, announces positive results from TELESTAR phase 3 study showing that telotristat etiprate is effective in the treatment of carcinoid syndrome caused by neuroendocrine tumors not adequately controlled by somatostatin analogs

Press Releases

2015-08-03-telotristat-etiprate-ph3-results-en1.pdf

July 30, 2015

Ipsen: 2015 half-year results

Press Releases

2015-07-31-pr-q2-sales-h1-2015-results-final2.pdf

July 30, 2015

Ipsen: 2015 half-year results and 2015 objectives

Financial results

2015-07-31-PR-Q2-sales-H1-2015-results-FINAL2.pdf

July 15, 2015

Ipsen announces FDA approval of Dysport® (abobotulinumtoxinA) for injection in the treatment of upper limb spasticity in adults in the United States

Press Releases

pr-aul-approval-final.pdf

July 1, 2015

Ipsen provides an update on 2020 strategy and outlook at Investor Day

Press Releases

pr-strategy-2020-en-final-final1.pdf

investor-day-02-07-2015-presentation-media-fr.pdf

June 2, 2015

Ipsen initiates a share buyback program Shares will be cancelled to compensate dilution resulting from its free share plans

Press Releases

pr-rachat-dactions-en-mup.pdf

June 1, 2015

Ipsen confirms its eligibility for PEA-PME

Press Releases

pr-pea-pme-confirm.pdf

May 28, 2015

Combined Shareholders’ Meeting of IPSEN S.A. held on 27 May 2015

Press Releases

communique-post-ag-2015-va-1.pdf

May 27, 2015

Combined Shareholders’ Meeting of 27 May 2015

Press Releases

2014-registration-document-2.pdf

agm-27-may-2015-results.pdf

agm-shareholders-meeting-notice.pdf

availability-of-preparatory-documentation-for-the-shareholders-meeting2.pdf

avis-de-convocation-balo-in-french-only.pdf

avis-prcalable-balo-in-french-only1.pdf

information-regarding-the-total-number-of-shares-and-voting-rights-as-at-15-april-2015-2.pdf

presentation-agm-2015-in-french-only.pdf

press-release-post-ag-2015.pdf

voting-or-proxy-form2.pdf

May 18, 2015

Ipsen strengthens its presence in the oncology field with the acquisition of OctreoPharm Sciences, a company developing innovative radiopharmaceuticals for the diagnosis and treatment of neuroendocrine tumours

Press Releases

pr-ipsen-octreopharm-en-final1.pdf

April 28, 2015

Ipsen reports strong sales growth in Q1 2015 and raises guidance for the year

Press Releases

pr-q1-15-sales-final-last-2.pdf

April 15, 2015

Active Biotech and Ipsen announce their decision to discontinue the development of tasquinimod in prostate cancer

Press Releases

16042015-ipsen-active-biotech-discontinuatio-10tasq10-final.pdf

April 7, 2015

Ipsen and Hannover Medical School start joint research in recombinant botulinum neurotoxins for targeted secretion inhibitors

Press Releases

08-04-2015-ipsen-hannover-medical-school-pr-final.pdf

March 31, 2015

Ipsen inaugurates new Cambridge, MA R&D center, at the heart of the most important biomedical research & innovation hub in the USA, to expand U.S. presence

Press Releases

pr-01-04-2015-cambridge-grand-opening-and-connecting-with-creativity-en.pdf

09-03-2015-ipsen_abstract_book-00.pdf

March 31, 2015

Ipsen expands ties to Harvard University with signing of a new Research Alliance Agreement

Press Releases

01-04-2015-pr-harvard-ipsen-2015-research-alliance-agreement.pdf

March 30, 2015

The Ipsen Group publishes its 2014 Registration document

Annual report

pr-ddr.pdf

March 3, 2015

Precisions concerning the resupply of Increlex® in the U.S.

Press Releases

precisions-increlex-resupply-150304.pdf

March 2, 2015

Ipsen’s 2014 results and 2015 financial objectives

Press Releases

pr-fy2014-results-final2.pdf

March 1, 2015

Dominique Laymand is appointed as Ipsen’s Senior Vice President, Chief Ethics and Compliance Officer

Press Releases

pr-appointment-dominique-laymand-final.pdf

March 1, 2015

Ipsen Announces Third Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2015

Press Releases

pr-increlex-resupply-3rd-batch-us-final.pdf

February 23, 2015

Ipsen enters into option agreement to acquire Canbex Therapeutics

Press Releases

24-02-2015-pr-canbex-ipsen-multiple-sclerosis-final-final1.pdf

February 2, 2015

Ipsen: sales in the fourth quarter and full year 2014

Press Releases

pr-fy14-sales-final.pdf

January 25, 2015

Ipsen announces topline results of two double-blind phase III studies of Dysport® in lower limb spasticity in children and in adults

Press Releases

26012015-pr-dysport-all-pll.pdf

January 6, 2015

Ipsen announces its corporate agenda for 2015

Press Releases

ipsen-2015-financial-agenda.pdf

December 15, 2014

François Garnier appointed Executive Vice President, General Counsel of Ipsen

Press Releases

12-2014-pr-francois-garnier_nathalie-joannes-general-counsel-en.pdf

December 15, 2014

Ipsen’s Somatuline® Depot® is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors

Press Releases

12-2014-corporate-pr-approval-somatuline-us-final.pdf

December 11, 2014

Ipsen announces that the International Breast Cancer Study Group (IBCSG) presented phase 3 results evaluating the use of ovarian suppression to adjuvant treatment with tamoxifen

Press Releases

12-12-2014-pr-ibcsg-decapeptyl-breast-cancer-en-final.pdf

November 27, 2014

Ipsen announces FDA acceptance of filing for Dysport® in the treatment of upper limb spasticity in adult patients

Press Releases

28-11-2014-pr-dysport-aul-sbla-final.pdf

November 19, 2014

Ipsen and CNRS create the “Archi-Pex” joint research and innovation lab, in collaboration with the University of Rennes 1 and CEA

Press Releases

rk-rev-20-11-2014-pr-ipsen-cnrs-joint-lab-archipex-final.pdf

November 17, 2014

Ipsen and the Salk Institute renew their agreement for discovery research in medical sciences

Press Releases

18-11-2014-pr-ipsen-salk-insitute-renewal-agreement-final1.pdf

November 5, 2014

Otonomy obtains rights to gacyclidine data from Ipsen to support development of OTO-311 as a treatment for tinnitus

Press Releases

06-11-2014-press-release-otonomy-and-ipsen-gacyclidine-en.pdf

October 28, 2014

Ipsen: sales in the 3rd quarter and first nine months of 2014

Financial results

29-10-2014-pr-first-9-months-2014-sales.pdf

October 21, 2014

Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate

Press Releases

22-10-2014-pr-ipsen-lexicon-telotristat-etiprate-carcinoid-syndrom-en1.pdf

October 9, 2014

Aymeric Le Chatelier joins Ipsen as Executive Vice President, Chief Financial Officer

Press Releases

10-10-2014-pr-appointment-aymeric-le-chatelier-cfo-final.pdf

October 9, 2014

Ipsen announces positive results from phase III clinical study of Decapeptyl® (triptorelin pamoate) 11.25 mg administered by subcutaneous route to prostate cancer patients

Press Releases

10-10-2014-pr-decapeptyl-subcutaneous-administration-prostate-cancer-final.pdf

October 1, 2014

Susheel Surpal steps down as Executive Vice President, Chief Financial Officer of Ipsen to pursue other opportunities

Press Releases

2014-10-02-pr-departure-susheel-surpal-final-final.pdf

September 26, 2014

Ipsen presents preliminary results of exploratory proof-of-concept study with tasquinimod in four advanced tumor types at the ESMO 2014 Congress

Press Releases

pr-27092014-tasq-phase-ii-umbrella-final.pdf

August 31, 2014

Ipsen announces acceptance of filings for Somatuline® in the treatment of GEP-NETs in the US with priority review and in Europe

Press Releases

2014-09-01-pr-acceptance-filing-somatuline-gep-net-us-eu-en.pdf

August 28, 2014

Ipsen: 2014 half-year results and 2014 objectives

Financial results

pr-h1-2014-final1.pdf

2014-h1-results-presentation-final.pdf

August 26, 2014

Ipsen North America Announces Second Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2014

Press Releases

8-26-14-ipsen-increlex-september-resupply-press-release-final.pdf

July 16, 2014

New England Journal of Medicine publishes Ipsen’s Somatuline® CLARINET® Phase III results in patients with metastatic gastroenteropancreatic neuroendocrine tumors

Press Releases

2014-07-17-clarinet-results-nejm-final.pdf

July 10, 2014

Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe

Press Releases

pr-ipsen-galderma-final.pdf

June 30, 2014

Ipsen submits marketing authorization applications in the US and Europe for Somatuline® (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Press Releases

pr-filing-somatuline-gep-net-us-eu-final.pdf

June 4, 2014

Ordinary Shareholders’ Meeting of 4 June 2014

Press Releases

1 – Preliminary notice to the Meeting – published in the French BALO (French only) – AGM 4 june 2014.pdf

2 – Information voting rights-shares – AGM 4 june 2014.pdf

3 – Shareholders’ meeting notice – published in the French BALO (French only) – AGM 4 june 2014.pdf

5 – Voting or proxy form – AGM 4 june 2014.pdf

6 – Availability and consultation of preparatory documentation for the AGM – AGM 4 june 2014.pdf

7 – Registration Document 2013 – AGM 4 june 2014.pdf

10 – Press Release post AGM – AGM 4 june 2014.pdf

June 3, 2014

Ordinary Shareholders’ Meeting of IPSEN S.A. held on 4 June 2014

Press Releases

04-06-2014-PR-general-shareholders-meeting-2014-EN.pdf

May 12, 2014

Ipsen announces a step forward in the resupply of Increlex® in the U.S.

Press Releases

13-05-2014-pr-increlex-resupply-us-final.pdf

April 29, 2014

Ipsen’s first quarter 2014 sales

Financial results

30042014-pr-q1-2014-sales-final3.pdf

April 27, 2014

Registration Document 2013

Annual report

ipsen_ddr_2013_va_clean1.pdf

April 11, 2014

Ipsen announces a first set of results on positive phase III clinical study of Dysport® in the treatment of adults suffering from Upper Limb Spasticity at the 8th World Congress for NeuroRehabilitation in Istanbul

Press Releases

12042014-pr-dysport-aul-wcnr-en-final-en.pdf

April 10, 2014

The Fondation Ipsen celebrates its 30th anniversary with a prestigious conference on the perspectives of cancer research, “Biology viewed through the prism of cancer”, attended by 8 Nobel Prize laureates and the greatest scientists in biomedical research

Press Releases

pr-30th-anniversary-fondation-ipsen-en.pdf

April 8, 2014

Ipsen eligible for PEA-PME and included in CAC® PME index by Euronext

Press Releases

pr-pea-pme-and-euronext-cac-pme-final-en.pdf

March 19, 2014

Ipsen announces that its controlling shareholder, Mayroy, sold approximately 7% of Ipsen’s share capital via private placement

Press Releases

pr-mayroy-shareholding-ipsen-en-final.pdf

March 17, 2014

Ipsen announces positive results from phase IIa clinical study of Dysport® in the treatment of patients with Neurogenic Detrusor Overactivity (NDO)

Press Releases

pr-dysport-ndo-phase-iia.pdf

February 27, 2014

Ipsen’s 2013 results and 2014 financial objectives

Financial results

28-02-2014-pr-fy2013-results_en.pdf

2013-annual-results-presentation.pdf

February 6, 2014

Ipsen announces positive top line results from phase III clinical study of Decapeptyl® (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with prostate cancer

Press Releases

pr-decapeptyl-results-3m-subcutaneous-administation.pdf

February 4, 2014

Ipsen announces clinical results of Dysport® Next Generation (DNG) and its intent to file the first ready-to-use liquid toxin A in Europe and ROW

Press Releases

05-02-2014-pr-dysport-next-generation-en.pdf

January 27, 2014

Ipsen: sales in the fourth quarter and full year 2013

Financial results

pr-fy13-sales.pdf

January 21, 2014

Ipsen implements a new governance in the United States to prepare for the launch of Somatuline® in oncology

Press Releases

pr-new-governance-us.pdf

January 16, 2014

Ipsen announces at ASCO GI that ELECT® clinical trial of Somatuline® in the control of symptoms in GEP-NET 1 patients with carcinoid syndrome met its primary endpoint

Press Releases

17012014_pr_elect_results_asco_gi_en.pdf

January 13, 2014

Ipsen and GW Pharmaceuticals plc enter into agreement for Ipsen to promote and distribute Sativex® in Latin America

Press Releases

14012014-pr-ipsen-gw-pharmaceuticals-sativex-latin-america-en.pdf

January 13, 2014

Ipsen to set up its own US oncology team for Somatuline® Depot® (lanreotide) Injection in neuroendocrine tumors

Press Releases

14-01-2014-pr-net-us.pdf

January 9, 2014

Jonathan Barnsley joins Ipsen as Executive Vice President, Technical operations

Press Releases

10-01-2014-pr-appointment-jonathan-barnsley-en.pdf

December 22, 2013

Ipsen announces its corporate agenda for 2014

Press Releases

23-12-2013-pf-corporate-agenda-2014-en.pdf

December 17, 2013

Ipsen prepares for the resupply of Increlex® in Europe

Press Releases

18122013-pr-increlex-resupply-eu_en.pdf

December 17, 2013

Ipsen and Mayoly Spindler enter into cross- promotion agreement for primary care activities in France

Press Releases

18-12-2013-pr-ipsen-mayoly-spindler-france.pdf

December 16, 2013

Ipsen announces positive initial results from the international double-blind clinical phase III study of Dysport ® in the treatment of Adults suffering from Upper Limb Spasticity

Press Releases

17122013-pr-dysport-aul-spasticity-en.pdf

December 11, 2013

Dominique Brard joins Ipsen as Executive Vice President, Human Resources

Press Releases

2013-12-12-pr-dominique-brard.pdf

December 2, 2013

The 13th Colloque Médecine et Recherche of the Fondation Ipsen in the Endocrinology series: “Brain Crosstalk in Puberty and Adolescence”

Press Releases

pr-brain-crosstalk-in-puberty-and-adolescence-eng.pdf

November 21, 2013

The 22nd Jean-Louis Signoret Neuropsychology Prize of the Fondation Ipsen has been awarded to Jean Decety (University of Chicago, Chicago, USA)

Press Releases

pr-jean-louis-signoret-prize-jean-decety-2013-en.pdf

November 5, 2013

Ipsen initiates a share buy-back program to partially cover its restricted share plans

Press Releases

06-11-2013-pr-restricted-share-plans-en.pdf

October 29, 2013

Ipsen: sales in the third quarter and first nine months of 2013

Financial results

30-10-2013-pr-q3-2013-sales-en.pdf

October 16, 2013

The 8th Cell Press / Days of Molecular Medicine Global Foundation / Fondation Ipsen meeting in the Exciting Biologies series: “Biology of boundaries”

Press Releases

17102013-pr-fondation-ipsen-biology-of-boundaries2.pdf

October 8, 2013

Active Biotech receives tasquinimod milestone payment from Ipsen for 10TASQ10 study

Press Releases

2013-10-09-tasq-milestone-pr.pdf

October 5, 2013

PeptiDream and Ipsen expand the scope of their collaboration for discovery of peptide drugs to treat serious endocrinologic disease

Press Releases

pr-ipsen-peptidream-collab-expansion-en.pdf

October 1, 2013

New organization project and composition of the Executive Committee to accelerate the implementation of Ipsen’s strategy

Press Releases

pr-new-organization_en_2oct2013.pdf

September 27, 2013

Ipsen announces that results from CLARINET® Phase III clinical trial presented at the 2013 European Cancer Congress showed the antiproliferative effect of Somatuline® (lanreotide) 120 mg injection in the treatment of non-functioning gastroentero and pancreatic neuroendocrine tumors (“GEP-NETs”)

Press Releases

pr-results-clarinet-esmo.pdf

September 25, 2013

Ipsen to relocate US R&D activities to Cambridge, MA in 2014

Press Releases

26-09-2013-pr-move-to-cambridge-en.pdf

September 16, 2013

Ipsen announces positive top line results from phase III ELECT® study of Somatuline® in the control of symptoms in NET patients with a history of carcinoid syndrome

Press Releases

pr-elect-primary-endpoint-en.pdf

August 29, 2013

Ipsen: 2013 half-year results and financial objectives

Financial results

pr-h1-2013-results-en.pdf

results-h1-2013.pdf

August 29, 2013

Detailed results of the phase III CLARINET study at the European Cancer Congress 2013 on 28 September 2013

Press Releases

pr-dates-late-breaking-news-and-press-conference-clarinet-en.pdf

July 14, 2013

Ipsen strengthens its neurology R&D capabilities with the acquisition of Syntaxin, a leader in recombinant botulinum toxin technology

Press Releases

20130715-pr-syntaxin-ipsen-en.pdf

July 14, 2013

Ipsen announce a sponsored research agreement with Harvard Medical School to discover novel engineered botulinum toxins for serious neurologic diseases

Press Releases

pr-harvard-ipsen.pdf

July 10, 2013

Ipsen announces positive results from phase III CLARINET study of Somatuline® Autogel® 120mg in gastrointestinal and pancreatic neuroendocrine tumors (“GEP-NETs”)

Press Releases

pr-clarinet-primary-endpoint-en.pdf

June 16, 2013

“PRIMARYS” study Investigators observed clinically relevant results in an investigational Phase III study with Somatuline® Autogel® 120 mg in patients with acromegaly

Press Releases

pr-endo-primarys-somatuline-en.pdf

June 13, 2013

Ipsen reorganizes its US neurology platform and confirms its goal to become profitable in the US in 2014

Press Releases

pr-dysport-us-reorganization-final-en.pdf

May 30, 2013

Combined Shareholders’ Meeting of IPSEN S.A. held on 31 May 2013

Press Releases

24-05-2013-pr-post-assemble-generale-en.pdf

May 29, 2013

24 th Neuronal Plasticity Prize of the Fondation Ipsen: Tim V.P. Bliss, Richard G. Morris and Yadin Dudai awarded for their works in the domain of “Mechanisms of memory”

Press Releases

pr_24th-neuronal-plasticity-prize_en.pdf

May 1, 2013

Combined Shareholders’ Meeting of 31 May 2013

Press Releases

1-avis-prealable-balo-du-17042013.pdf

2-17042013_droits-de-vote-gb.pdf

3-avis-de-convocation-balo.pdf

convocation_va_ipsen-ven.pdf

formulaire-de-vote_2.pdf

ddr_2012_en.pdf

7-communique-mise-a-dispo-doc-ag-vgb.pdf

presentation-agm-31-mai-2013.pdf

ipsen-sa-ag-31-mai-resultats-vgb.pdf

May 1, 2013

Availability of documentation for the Shareholders’ Meeting

Press Releases

20130602_-ipsen-mise-a-dispo-doc-ag-gb.pdf

April 24, 2013

Ipsen’s first quarter 2013 sales

Financial results

2013-04-25-pr-q1-2013-sales.pdf

April 24, 2013

Active Biotech and Ipsen update the analysis plan for the 10TASQ10 trial evaluating tasquinimod in the treatment of prostate cancer

Press Releases

2013-04-25-pr-tasquinimod-analysis-plan-10tasq10-final.pdf

April 24, 2013

Ipsen expects Increlex® supply interruption due to supplier manufacturing issues

Press Releases

2013-04-25-pr-increlex-supply-interruption.pdf

April 23, 2013

Combined Shareholders’ Meeting of Ipsen on 31 May 2013: Proposals of renewal of the terms of office of two Directors and appointment of a new Director

Press Releases

2013-04-24-pr-appointment-martha-crawford-board-of-directors-en.pdf

April 22, 2013

The 21st Colloque Médecine et Recherche of the Fondation Ipsen in the Neurosciences series: “New frontiers in social neuroscience”

Press Releases

pr-ipsen-neurosciences-new-frontiers-in-social-neuroscience-en.pdf

April 9, 2013

Pepti Dream and Ipsen enter into a collaboration for advancing drug discovery efforts for peptides to treat serious disease

Press Releases

04-2013-pr-peptidream-ipsen-joint-en.pdf

April 8, 2013

Ipsen’s Dysport® approved for use in aesthetic medicine in Canada to be marketed by Medicis Aesthetics Canada

Press Releases

pr-ipsen-valeant-dysport-canada-aesthetics-en.pdf

March 26, 2013

The Ipsen Group publishes its 2012 Registration document

Annual report

DDR_2012_EN.pdf

March 20, 2013

Ipsen and Inspirations Biopharmaceuticals announce closing of the sale of OBI-1 to Baxter International

Press Releases

pr-ipsen-closing-obi-1-sale-to-baxter.pdf

February 26, 2013

Ipsen’s 2012 results and 2013 financial objectives

Financial results

ipsen-fy-2012-results-presentation1.pdf

pr-fy2012-results1.pdf

February 26, 2013

Christel Bories joins Ipsen as Deputy Chief Executive Officer

Press Releases

pr-appointment-christel-bories_en.pdf

February 19, 2013

Ipsen and Inspiration Biopharmaceuticals announce closing of the IB1001 sale to Cangene Corporation

Press Releases

pr-ipsen-cangene-closing-ib1001-fix-en-final.pdf

February 6, 2013

Eziclen® / Izinova® a new product for bowel cleansing successfully completed European decentralised registration procedure

Press Releases

pr-ipsen-braintree-bli800-eu-approval1.pdf

February 5, 2013

Ipsen and Inspiration Biopharmaceuticals enter into an Asset Purchase Agreement with Cangene Corporation on IB1001

Press Releases

06022013-pr-ipsen-inspiration-cangene-fix-ib1001-en1.pdf

January 29, 2013

Ipsen’s fourth quarter and full year 2012 sales

Financial results

2013-30-01-pr-fy2012-sales-en.pdf

January 23, 2013

Ipsen and Inspiration Biopharmaceuticals enter into an Asset Purchase Agreement with Baxter International on OBI-1

Press Releases

pr-ipsen-obi-1-asset-purchase-agreement-en1.pdf

January 16, 2013

Teijin Pharma to launch Ipsen’s Somatuline® subcutaneous injection in the treatment of acromegaly and pituitary gigantism in Japan

Press Releases

pr-ipsen-teijin-somatuline-launch_joint-press-release-en.pdf

January 2, 2013

Ipsen’s corporate agenda for 2013

Press Releases

03012013-pr-financial-agenda_2013-en.pdf

December 17, 2012

Oncodesign and the Laboratory for Neurobiology and Gene Therapy at the KU Leuven enter into a research collaboration for advancing drug discovery efforts with Ipsen in Parkinson’s disease

Press Releases

pr-oncodesign-ipsen-ku-leuven-en.pdf

December 9, 2012

Active Biotech and Ipsen announce completion of recruitment of tasquinimod clinical phase III study in prostate cancer

Press Releases

pr-tasq-full-recruitment-phase-iii-mcrpc.pdf

December 4, 2012

The 12nd Colloque Médecine et Recherche of the Fondation IPSEN in the Endocrinology series: “Hormones, intrauterine health and programming”

Press Releases

20121205-pr-hormones-intrauterine-health-and-programming.pdf

December 3, 2012

The 21th Jean-Louis Signoret Neuropsychology Prize of the Fondation Ipsen has been awarded to Cathy Price (University College London, London, UK)

Press Releases

20121204-pr-jean-louis-signoret-prize-2012-cathy-price-en.pdf

December 2, 2012

Ipsen and Galderma increase their collaboration for Dysport® in new territories

Press Releases

pr-ipsen-galderma-new-agreements-final.pdf

November 19, 2012

Ipsen and Inspiration Biopharmaceuticals announce that OBI-1 has received Fast Track designation from FDA for acquired hemophilia A

Press Releases

pr-ipsen-inspiration-obi-1-fast-track-en.pdf

November 18, 2012

The 2012 Fondation Ipsen Longevity Prize has been awarded to Prof. Linda Fried for her outstanding work on the frailty syndrome

Press Releases

20121119-pr-longevity-prize-2012-linda-fried-en.pdf

October 30, 2012

Ipsen’s hemophilia partner, Inspiration Biopharmaceuticals, seeks Chapter 11 protection

Press Releases

31102012_ipsen-hemophilia.pdf

pr-inspiration-chapter-11-en.pdf

October 28, 2012

Ipsen’s third quarter and first nine months 2012 sales

Press Releases

pr-sales-q3-2012-final-def.pdf

October 24, 2012

The 2nd meeting of the series Days of Molecular Medicine – « The Translational Science of Rare Diseases : From Rare to Care »

Press Releases

20121025-pr-fondation-ipsen-days-of-molecular-medicine-2012-en.pdf

October 18, 2012

Ipsen to initiate a proof-of-concept study with tasquinimod in additional cancer indications

Press Releases

pr-tasq-poc-phase-ii-4-indications-en.pdf

October 2, 2012

Ipsen provides update on recent agreement with Inspiration

Press Releases

pr-ipsen-update-inspiration-en.pdf

October 2, 2012

Ipsen initiates a phase II “Switch maintenance” trial in metastatic castrate-resistant prostate cancer with tasquinimod

Press Releases

pr-ipsen-active-biotech-tasq-switch-maintenance-ph-ii-en.pdf

September 30, 2012

Tasquinimod Biomarker Phase II data presented at ESMO 2012

Press Releases

pr-tasq-biomarkers-esmo-en.pdf

September 19, 2012

The 11th Endocrine Regulation Prize of the Fondation Ipsen is awarded to Dr Jeffrey M. Friedman

Press Releases

20120920-pr-endocrine-regulation-prize-2012-en.pdf

September 9, 2012

Ipsen maintains Increlex® (mecasermin [rDNA origin] injection) supply in the US

Press Releases

pr-increlex-us-en.pdf

August 27, 2012

Ipsen’s half-year 2012 Results

Press Releases

pr_h1_2012_en.pdf

1h12-results-analyst-presentation_0.pdf

August 20, 2012

Ipsen and Inspiration Biopharmaceuticals renegotiate strategic partnership agreement

Press Releases

pr_ipsen_and_inspiration_renegotiate_strategic_partnership.pdf

July 24, 2012

23rd Neuronal Plasticity Prize of the Fondation Ipsen: Catherine Dulac, Michael Meaney and J. David Sweatt awarded for their pioneer works in the domain of “Epigenetic and brain function”

Press Releases

20120725-pr_23rd-neuronal-plasticity-prize_en.pdf

July 10, 2012

Ipsen decides to retain the Dreux-based primary care industrial facility within the Group’s scope

Press Releases

pr-ipsen-dreux-en.pdf

July 9, 2012

Ipsen’s partner Inspiration Biopharmaceuticals announces hold of phase III clinical trials evaluating IB1001 for the treatment and prevention of hemophilia B

Press Releases

pr_ib1001-clinical-hold_en_0.pdf

June 28, 2012

Ipsen’s Somatuline® receives marketing approval in Japan for the treatment of acromegaly and pituitary gigantism

Press Releases

pr-ipsen-approval-somatuline-japan-en.pdf

June 3, 2012

Active Biotech’s and Ipsen’s Tasquinimod shows encouraging overall survival improvement in castrate resistant prostate cancer

Press Releases

pr-ipsen-active-biotech-asco-curtain-raiser-en_0.pdf

May 31, 2012

Combined Shareholders’ Meeting of IPSEN S.A. held on 1 June 2012

Press Releases

pr-ipsen-post-general-assembly-meeting-en.pdf

May 20, 2012

600 Patients Recruited in Active Biotech’s and Ipsen’s tasquinimod Clinical Phase III Study

Press Releases

pr-ipsen-active-biotech-tasq-600-patients-en.pdf

May 17, 2012

Active Biotech and Ipsen to present Tasquinimod Phase II Overall Survival data at the 2012 ASCO Annual Meeting

Press Releases

pr-ipsen-active-biotech-asco-curtain-raiser-en.pdf

May 10, 2012

The 10th Endocrine Regulation Prize of the Fondation Ipsen is awarded to Paolo Sassone-Corsi

Press Releases

20120511-pr-endocrine-regulation-prize-2011-en.pdf

May 3, 2012

Combined General Meeting of 1 June 2012

Press Releases

1-ipsen-avis-prealable-balo-06042012.pdf

2-ipsen-06042012_ddroits-de-vote-gb.pdf

3-avis-de-convocation-balo-04052012.pdf

4-shareholders-meeting-notice-2012.pdf

5-formulaire-ag-01062012_0.pdf

6-2011-registration-document.pdf

7-communique-mise-a-dispo-doc-ag-gb.pdf

8-presentation-agm-1-juin-2012.pdf

9-ipsen-sa-ag-1-juin-2012-resultats-va.pdf

May 3, 2012

Availability of preparatory documentation for the Shareholders’ Meeting

Press Releases

20120504-communique-mise-a-dispo-doc-ag-en.pdf

May 2, 2012

Ipsen’s first quarter 2012 sales

Financial results

pr_q1_2012_sales_en.pdf

April 24, 2012

Ipsen pursues its development in the United States with the opening of its new commercial headquarters in New Jersey (NJ)

Press Releases

pr-opening-new-jersey-offices-en.pdf

April 16, 2012

Ipsen’s partner, Inspiration Biopharmaceuticals, announces US filing of Biologics License Application (BLA) for IB1001, a recombinant factor IX product for the treatment of hemophilia B

Press Releases

pr-ipsen-ib1001-us.pdf

April 2, 2012

The 20th Colloque Médecine et Recherche of the Fondation Ipsen in the Neurosciences series: “Programmed cells: from basic neuroscience to therapy”

Press Releases

20120403-pr-fondation-ipsen-neurosciences-programmed-cells-en.pdf

April 1, 2012

The Ipsen Group publishes its 2011 Registration document

Annual report

pr-registration-document-2011-en.pdf

February 28, 2012

Ipsen’s 2011 results and 2012 objective

Press Releases

pr-fy2011-results-en_0.pdf

fy-2011-results-analyst-presentation-final-internet.pdf

February 27, 2012

The 27 th Colloque Médecine et Recherche of the Fondation Ipsen in the Alzheimer Disease series: “Proteopathic Seeds and Neurodegenerative Diseases”

Press Releases

20120228-pr-proteopathic-seeds-and-neurodegenerative-diseases_en.pdf

February 23, 2012

Active Biotech and Ipsen report Tasquinimod (TASQ) phase II long term safety data at the 27th European Association of Urology (EAU) Congress

Press Releases

pr-ipsen-active-biotech-phase-ii-safety-tasq.pdf

February 1, 2012

Ipsen’s fourth quarter and full year 2011 sales and other significant developments

Press Releases

fy-2011-sales-presentation_0.pdf

pr-fy11-sales-en.pdf

January 26, 2012

Ipsen acknowledges Tanakan® delisting in France

Press Releases

pr-delisting-tanakan-en_0.pdf

January 23, 2012

Santhera and Ipsen Renegotiate Fipamezole Licensing Agreement

Press Releases

pr-santhera-ipsen-fipamezole-en.pdf

January 22, 2012

Fifth meeting in the “Biological Complexity” series jointly organised by the Fondation Ipsen and the Salk Institute for Biological Studies

Press Releases

20120123-pr-immunity-and-inflammation-en.pdf

January 4, 2012

Oncodesign and Ipsen enter into a research collaboration for the development of new therapeutic agents against the LRRK2 Parkinson’s disease target

Press Releases

pr-oncodesign-ipsen_en.pdf

January 3, 2012

Ipsen announces its corporate agenda for 2012

Press Releases

pr-financial-agenda_2012_en.pdf

December 1, 2011

The 20th Jean-Louis Signoret Neuropsychology Prize of the Fondation Ipsen is awarded to Prof. Patricia K. Kuhl (University of Washington, Seattle, USA)

Press Releases

20121202-pr-neuropsychology-prize-patricia-k-kuhl-en.pdf

November 28, 2011

The 11st Colloque Médecine et Recherche of the Fondation Ipsen in the Endocrinology series: “Multiple origins of sex differences in brain. Neuroendocrine functions and their pathologies.”

Press Releases

20111129-pr-endocrinology-sex-differences-in-brain-en.pdf

November 27, 2011

Ipsen’s partner Inspiration Biopharmaceuticals announces the initiation of the second phase III pivotal clinical study of OBI-1 in congenital hemophilia A with inhibitors

Press Releases

pr-obi-1-2nd-phase-iii-congenital-hemophilia-a-en.pdf

November 22, 2011

16th Longevity Prize of La Fondation Ipsen: Professor Thomas Kirkwood is awarded in recognition of his outstanding leadership in the domain of “Theoretical approach to the biology of longevity”

Press Releases

20111123-pr-thomas-kirkwood-16th-longevity-prize_en.pdf

November 1, 2011

Ipsen sells the North American development and marketing rights for Apokyn® to Britannia Pharmaceuticals, achieving a key milestone in the execution of its new North American strategy

Press Releases

pr-sales-apokyn-britannia-pharmaceuticals_en.pdf

October 26, 2011

Ipsen’s first nine months of 2011 sales

Press Releases

pr-q3-2011-sales_en.pdf

October 19, 2011

Syntaxin and Ipsen enter into a strategic agreement to develop novel botulinum-toxin therapeutics

Press Releases

pr-syntaxin-ipsen-en_0.pdf

October 2, 2011

Ipsen’s partner, Inspiration Biopharmaceuticals, announces acceptance of European marketing authorization application for IB1001 for the treatment of hemophilia B

Press Releases

pr-ipsen-ib1001-eu-approval-filing-final-en.pdf

September 26, 2011

Ipsen in-licenses from Photocure Hexvix®, the first approved & marketed drug for improved detection of bladder cancer, a key step in the surgical resection

Press Releases

pr-ipsen-hexvix-en.pdf

August 29, 2011

Appointments to Ipsen’s Executive Committee: Nathalie Joannes is nominated Executive Vice President, General Counsel and Susheel Surpal is nominated Executive Vice President, Chief Financial Officer

Press Releases

pr-appointments-comex_en.pdf

August 29, 2011

Ipsen’s half-year 2011 Results

Financial results

pr-ipsen-results-h1-2011-en.pdf

ipsen_h1_2011_results_0.pdf

August 29, 2011

Inspiration Biopharmaceuticals and Ipsen Expand their Partnership in Preparation for the Commercial Launch of Inspiration’s Hemophilia Pipeline in Europe

Press Releases

pr-ipsen-inspiration-eu-business-unit-hemophilia-en.pdf

July 27, 2011

Ipsen’s partner Inspiration Biopharmaceuticals announces data from OBI-1 pivotal stage program in Hemophilia at 23 rd ISTH congress

Press Releases

20110728-pr-_ipsen_obi-1-isth-en.pdf

July 18, 2011

22nd Neuronal Plasticity Prize of the Fondation Ipsen: Helen J. Neville, Isabelle Peretz and Robert J. Zatorre awarded for their pioneering research into the domain of “Music and Brain Plasticity”

Press Releases

20120719-pr_22nd-neuronal-plasticity-prize_en.pdf

July 11, 2011

Ipsen and Institut de cancérologie Gustave Roussy enter into a partnership agreement

Press Releases

20110712_pr_igr_partnership_agreement_en.pdf

July 11, 2011

Renewal of agreement between Ipsen and the Salk Institute supports cutting-edge research

Press Releases

20110712-pr-ipsen_salk-en.pdf

June 8, 2011

Increase focus, invest to grow, leverage footprint: Ipsen’s new strategy

Press Releases

pr-strategy-2020-en-final.pdf

strategy-day-june-9-presentation.pdf

June 5, 2011

Ipsen announces discontinuation of the development of Irosustat in monotherapy

Press Releases

pr-irosustat_en.pdf

May 26, 2011

Change within Ipsen’s Executive Committee

Press Releases

pr_claire-giraut_en.pdf

May 26, 2011

Combined Shareholders’ Meeting of Ipsen S.A. held on 27 May 2011

Press Releases

pr_ipsen_post_shareholders_meeting_052711_en1.pdf

May 26, 2011

Combined General Meeting of 27 May 2011

Press Releases

avis-balo.pdf

08042011-total-number-of-shares-and-voting-rights.pdf

3_avis-de-convocation-publie-au-balo.pdf

avis-de-convocation-2011-va.pdf

formulaire-de-vote_0.pdf

ddr_ipsen_2010_en1.pdf

communique-mise-a-dispo-doc-ag-04052011-va.pdf

presentation-ag-27-mai-2011_0.pdf

9_resultatsvotes_en.pdf

May 10, 2011

Appointment of Etienne de Blois as Ipsen’s Executive Vice-President, Human Resources

Press Releases

pr_etiennedeblois_en_0.pdf

May 9, 2011

The 26th Colloque Médecine et Recherche of the Fondation Ipsen in the series Alzheimer Disease : “Protein Quality Control in Neurodegenerative Diseases”

Press Releases

20110510-pr_fondation_alzheimers-disease.pdf

May 3, 2011

Combined Shareholders’ Meeting : Availability of preparatory documentation

Press Releases

communique-mise-a-dispo-doc-ag-04052011-va-1.pdf

May 2, 2011

Ipsen’s first quarter 2011 sales

Financial results

pr-q1-2011-sales-final-en.pdf

May 1, 2011

Changes within Ipsen’s Executive Committee

Press Releases

02052011_pr_st-fb-_en.pdf

April 26, 2011

The Ipsen Group publishes its 2010 Registration document

Annual report

cp-ddr2010-uk.pdf

April 18, 2011

The 19th Colloque Médecine et Recherche of the Fondation Ipsen in the Neuroscience series: “Epigenetics, Brain and Behavior

Press Releases

20110419-pr_fondation_neurosciences_epigenetics_brain_behavior.pdf

April 17, 2011

Active Biotech and Ipsen enter into a broad partnership for the co-development and commercialization of TASQ in uro-oncology

Press Releases

pr_ipsen_active_biotech_en.pdf

March 8, 2011

The FDA approves Somatuline® Depot (lanreotide) Injection Extended Dosing Interval as part of Ipsen’s Prior Approval Supplement application

Press Releases

20110309-pr-somatuline-depot-edi-final-en.pdf

March 1, 2011

Ipsen’s 2010 results and 2011 sales objective

Press Releases

pr-fy2010-ipsen-results.pdf

fy-2010-results.pdf

February 24, 2011

Ipsen and bioMérieux enter into a broad partnership in personalized medicine

Press Releases

pr-ipsen-biomerieux-theranostics-partnership-20110225_en.pdf

February 2, 2011

Ipsen’s partner Inspiration Biopharmaceuticals announces non-inferiority of IB1001, its recombinant factor IX for Hemophilia B

Press Releases

pr-ipsen-ib1001-pk-final.pdf

February 1, 2011

Ipsen’s fourth quarter and full year 2010 sales and other significant developments

Financial results

pr-full-year-2010-sales-final.pdf

full_year_2010_sales_0.pdf

December 22, 2010

Ipsen announces its corporate agenda for 2011

Press Releases

pr_ipsen-corporate-agenda-2011_en.pdf

December 14, 2010

Ipsen closes its BIM 23A760 trials

Press Releases

pr-ipsen-bim-23a760-en-final.pdf

December 1, 2010

The 19th Jean-Louis Signoret Neuropsychology Prize of the Fondation Ipsen is awarded to Prof. Giacomo Rizzolati (University of Parma, Parma, Italy)

Press Releases

20101202-pr-neuropsychology-prize-giacomo-rizzolati-en.pdf

November 29, 2010

10th Colloque Médecine et Recherche of the Fondation Ipsen in the Endocrinology series: “Multi-system Endocrine Disruption”

Press Releases

20101030-pr-multi-system-endocrine-disruption-en.pdf

November 22, 2010

Professor Judith Campisi is awarded in recognition of the outstanding work she has been carrying in the domain of longevity, senescence and cancer

Press Releases

20121123-pr-15th-longevity-prize_en.pdf

November 18, 2010

Ipsen’s partner Inspiration Biopharmaceuticals announces the treatment of the first patient in phase III pivotal study of OBI-1 for acquired hemophilia A

Press Releases

pr-ipsen-obi-phase-iii-en-final_1.pdf

October 27, 2010

Ipsen first’s nine months of 2010 Sales

Financial results

pr-sales-q3-2010-final-en.pdf

October 18, 2010

OBI-1 Receives Orphan Drug Designation in Europe

Press Releases

pr-obii-1-orphan-drug-status-granted-by-ec-final-en.pdf

October 10, 2010

Ipsen sells its shares in PregLem Holding SA to Gedeon Richter Plc

Press Releases

pr_preglem_final_en.pdf

October 10, 2010

Ipsen’s Board of Directors announces Jean-Luc Bélingard’s departure and the appointment of Marc de Garidel as new Chairman and CEO

Press Releases

pr-jl-belingard-marc-de-garidel-en.pdf

October 10, 2010

“Cell Biology in Recognition”

Press Releases

20101011-pr-biology-of-recognition-en.pdf

September 2, 2010

Santhera and Ipsen Enter into Licensing Agreement Santhera and Ipsen Enter into Licensing Agreement in Parkinson’s Disease

Press Releases

pr-joint-santhera-ipsen_fipamezole-final-en.pdf

August 30, 2010

Ipsen’s Half-year 2010 Results

Financial results

pr_h1_2010-results_en.pdf

ipsen_h1_2010_results_presentation_0.pdf

Choose your location:

Choose a Language

Ipsen presents its 2019 results, provides 2020 guidance and updates 2022 financial outlook

Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria

Ipsen appoints Steven Hildemann, MD., PhD as Executive Vice President, Chief Medical Officer

Dysport® (clostridium botulinum type A toxin-haemagglutinin complex) now approved in the UK for symptomatic treatment of upper limb spasticity in children with cerebral palsy

Ipsen Announces Departure of David Meek as Chief Executive Officer

Ipsen Initiates Partial Clinical Hold for Palovarotene IND120181 and IND135403 Studies

Ipsen appoints Howard Mayer, M.D. as Executive Vice President and Head of Research and Development

Proposed reclassification of Ipsen shares held by Mayroy

Ipsen presents new analyses utilizing modern data mining approaches at ISPOR Europe 2019

Ipsen delivers strong double-digit sales growth for the third quarter of 2019 and confirms full year 2019 guidance

Ipsen and Blueprint Medicines announce exclusive global license agreement to develop and commercialize BLU-782 for the treatment of fibrodysplasia ossificans progressiva (FOP)

Ipsen showcases studies at the ESMO 2019 Congress highlighting progress in new approaches for difficult-to-treat cancers

Ipsen announces positive results from Phase IIIb/IV ENGAGE study of the combination of Dysport® (abobotulinumtoxinA) with Guided Self-rehabilitation Contracts in adult patients with upper and lower limb spastic hemiparesis

Ipsen to present new data at 13th Annual Conference of the International Liver Cancer Association (ILCA 2019)

Ipsen and Servier announce initial Phase II/III clinical data evaluating investigational liposomal irinotecan (ONIVYDE®) as a second-line treatment for small cell lung cancer (SCLC) at the IASLC 2019 World Conference on Lung Cancer

Ipsen delivers strong results for the first half of 2019 with robust double-digit sales growth and improved Core Operating margin and upgrades its guidance for full year 2019

Ipsen and Servier announce initial Phase 1/2 clinical data evaluating liposomal irinotecan (ONIVYDE®) as an investigational first-line treatment for metastatic pancreatic cancer at ESMO 21st World Congress on Gastrointestinal Cancer

Disclosure of transactions in own shares between 18/06/2019 and 21/06/2019

Ipsen initiates a share buyback program to cover its new free share allocation plan

Debiopharm and Ipsen extend their strategic Decapeptyl® (triptorelin) partnership for another 15 years

New investigational clinical data for Ipsen’s oncology products in 11 solid tumor types to be presented at 2019 ASCO Annual Meeting

Ipsen to host an Investor Day to highlight its innovative R&D pipeline and provide financial outlook for 2022

Ipsen reports strong double-digit sales growth in First Quarter 2019 and confirms Full Year 2019 financial targets

Ipsen Completes Acquisition of Clementia Pharmaceuticals

Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A.

Clementia Pharmaceuticals Inc. Shareholders Approve Plan of Arrangement With Ipsen S.A.

Ipsen publishes its 2018 Registration Document

Ipsen to Present Improvements to Somatuline® Autogel® Pre-filled Syringe at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference

Ipsen to Present New Data on Enhancement of Patient Care at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference

Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio

Ipsen delivers strong 2018 results and expects continued sales and profit growth in 2019

Patients living with spasticity want long-lasting symptom relief

Ipsen presents the results of the first in-human study of a recombinant fast-acting neurotoxin (rBoNT-E) at TOXINS 2019

Ipsen demonstrates leadership position in neurotoxin research with strong presence at TOXINS 2019

Exelixis and Ipsen initiate phase 3 pivotal trial (COSMIC-312) of cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced hepatocellular carcinoma

Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide (IPN01087)

European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the treatment of hepatocellular carcinoma in adults previously treated with sorafenib

Ipsen delivers strong sales growth of 20.2% for the third quarter of 2018 and confirms full year guidance

Ipsen to present new data from its oncology portfolio at the 2018 European Society for Medical Oncology (ESMO) congress

Ipsen receives positive CHMP opinion for Cabometyx® (cabozantinib) for the second-line treatment of patients with hepatocellular carcinoma (HCC)

Ipsen receives positive CHMP opinion for Cabometyx® (cabozantinib) for the second-line treatment of patients with hepatocellular carcinoma (HCC)

Ipsen delivers strong results for the first half of 2018 with sales growth of 21.5% and upgrades its guidance for full year 2018

Ipsen and BioLabs to open new Innovation Center in Cambridge (U.S.) to foster development of new therapies for patients

Ipsen announces new clinical data to be presented at ISPRM 2018 demonstrating commitment to neurotoxin research

Ipsen announces CELESTIAL phase 3 pivotal trial results in the New England Journal of Medicine

Ipsen initiates a share buyback program to cover its free share allocation and employee share plans

Combined Shareholders’ Meeting of 30 May 2018

Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at the Combined Shareholders’ Meeting on 30 May 2018

Ipsen announces clinical data to be presented at ASCO demonstrating its commitment to patients with cancer

Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development Partnership

European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma

Ipsen reports strong first quarter 2018 sales growth of 23.1% at constant exchange rates

Ipsen announces EMA validation of filing of a new application for additional indication for Cabometyx®, for patients with previously treated advanced Hepatocellular Carcinoma (HCC).

Ipsen publishes its 2017 Registration Document

Ipsen receives positive CHMP opinion for Cabometyx® (cabozantinib) for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma

Ipsen appoints Ivana Magovčević-Liebisch Ph.D., J.D. and Régis Mulot to Executive Leadership Team

Ipsen announces 18 posters to be presented at the 15th Annual ENETS Conference

Arix Bioscience and Ipsen sign a strategic agreement to develop and commercialise innovative therapies

Ipsen delivers strong 2017 results with 21.1%﻿﻿ sales growth and Core operating margin increase of 3.4 points and expects significant further growth in sales and margin in 2018

Ipsen announces eight oral presentations from its Neurosciences portfolio at the 10th World Congress for Neurorehabilitation (WCNR)

Dr Sotirios G. Stergiopoulos appointed as Ipsen Chief Medical Officer

Ipsen announces 13 posters and 1 oral presentation at the 2018 ASCO Gastrointestinal Symposium

Ipsen and Exelixis announce phase 3 trial results of cabozantinib demonstrating significant overall survival benefit in patients with previously treated advanced hepatocellular carcinoma

Ipsen appoints Richard Paulson Executive Vice-President and Chief Executive Officer of Ipsen North America

Ipsen announces it is no longer eligible for the PEA-PME scheme

Ipsen announces its corporate agenda for 2018

Ipsen announces publication in Neurology of results of two studies demonstrating the efficacy and safety of Dysport® (abobotulinumtoxinA) in adult patients with lower limb spasticity

Ipsen delivers strong sales growth of 22.6% for the third quarter of 2017 and confirms full year guidance

Ipsen announces that phase 3 CELESTIAL trial of cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma

Ipsen receives approval from European Commission for Xermelo® (telotristat ethyl) for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analogue therapy

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome

Ipsen and Exelixis announce results from Phase 2 CABOSUN trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma at ESMO 2017

Ipsen receives validation from European Medicines Agency for the application of a new indication for Cabometyx® (cabozantinib) for first-line treatment of advanced renal cell carcinoma in adults

Ipsen announces 16 abstract presentations of oncology portfolio at European Society of Medical Oncology congress

Exelixis submits U.S. supplemental new drug application for Cabometyx®(Cabozantinib) for the treatment of previously untreated advanced kidney cancer

Ipsen delivers strong sales growth of 18.8% in the first half of 2017 and upgrades its guidance for full year 2017

Ipsen receives positive CHMP opinion for approval of Xermelo® (telotristat ethyl), for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analogue therapy

Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETY or Opdivo and Yervoy® in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma.

Ipsen delivers strong 2017 results with 21.1% sales growth and Core operating margin increase of 3.4 points and expects significant further growth in sales and margin in 2018

Exelixis submits U.S. supplemental new drug application for Cabometyx^®(Cabozantinib) for the treatment of previously untreated advanced kidney cancer

Ipsen Announces FDA Approval of Dysport^® (abobotulinumtoxinA) for injection for the treatment of Lower Limb Spasticity in children aged two and older.

Supplemental Application Filed for Somatuline^®in Japan for Additional Indication of Neuroendocrine Tumors

Ipsen annonce l’autorisation par la FDA de Dysport^® (abobotulinumtoxinA) injection dans le traitement de la spasticité des membres inférieurs chez l’enfant âgé de 2 ans et plus

Ipsen announces publication in Pediatrics of the results of the phase III randomized study showing the efficacy and safety of Dysport^® (abobotulinumtoxinA) in children with dynamic equinus foot deformity due to cerebral palsy

Ipsen and Galderma expand current distribution agreement for Dysport^® in aesthetic indications to some key Asia-Pacific territories